Comparison of cancer prevalence between patients with glomerulonephritis and the general population at the time of kidney biopsy

Autoři: Jiwon Ryu aff001;  HyunJin Ryu aff002;  Sejoong Kim aff003;  Ho Jun Chin aff003;  Ki Young Na aff003;  Dong-Wan Chae aff003;  Hyung-Jin Yoon aff005
Působiště autorů: Department of Internal Medicine, Cheju Halla General Hospital, Cheju, Republic of Korea aff001;  Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea aff002;  Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea aff003;  Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea aff004;  Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul, Republic of Korea aff005
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0224024


Glomerulonephritis (GN) has been associated with many solid and hematologic malignancies. However, cancer prevalence at the time of GN diagnosis has been rarely examined. We aimed to evaluate the cancer prevalence in patients with GN at the time of kidney biopsy and to compare the results to those of the general population. A total of 1,155 patients who underwent kidney biopsy between 2003 and 2017 were included. We investigated patients diagnosed with cancer within one month of kidney biopsy. The occurrence of cancer was compared with that of the Korean general population using the observed-to-expected rates (O/E ratio). Twenty-nine patients with GN had cancer. The mean age of patients with and without cancer was 49 and 66 years old, respectively. The proportion of male patients with and without cancer was 49.4% and 58.6%, respectively. The glomerular filtration rate was different between the groups (78.1 ± 37.0, 58.0 ± 43.6 ml/min/1.73 m2, p = 0.006), but the urine protein/creatinine ratio was not (3.21 ± 4.01, 5.38 ± 7.47 g/gCr, p = 0.172). Immunoglobulin A nephropathy (IgAN) was the most common GN (37.9%), followed by membranous GN (13.5%), focal segmental glomerulosclerosis (9.7%), minimal change disease (9.2%), amyloidosis (1.2%). Amyloidosis was the most common GN associated with malignancy (20.7%). In patients with amyloidosis, cancer was observed almost 28 times more than expected and these patients showed higher cancer occurrence than patients with other GN (Relative Risk [RR]: 15.73; 95% confidence interval [CI]: 4.82–51.30; p < 0.01). Cancer occurrence was three times greater in GN patients aged > 50 years compared to the general population (O/E ratio: 3.42; 95% CI: 1.37–5.46; p = 0.027). Patients with GN, especially amyloidosis, have higher risk of cancer than the general population at the time of GN diagnosis. Older age (> 50 years) was one of the major determinants of the presence of cancer in GN patients.

Klíčová slova:

Biopsy – Cancer detection and diagnosis – Kidneys – Nephritis – Amyloidosis – Glomerulonephritis – Tin


1. Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int. 1999;56(1):355–77. doi: 10.1046/j.1523-1755.1999.00548.x 10411717

2. Bacchetta J, Juillard L, Cochat P, Droz JP. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol. 2009;70(1):39–58. Epub 2008/09/16. doi: 10.1016/j.critrevonc.2008.08.003 18790651.

3. Cambier JF, Ronco P. Onco-nephrology: glomerular diseases with cancer. Clin J Am Soc Nephrol. 2012;7(10):1701–12. Epub 2012/08/21. doi: 10.2215/CJN.03770412 22904123.

4. Lee JC, Yamauchi H, Hopper J. The association of cancer and the nephrotic syndrome. Ann Intern Med. 1966;64(1):41–51. doi: 10.7326/0003-4819-64-1-41 5900782

5. Jhaveri KD, Shah HH, Calderon K, Campenot ES, Radhakrishnan J. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int. 2013;84(1):34–44. Epub 2013/02/01. doi: 10.1038/ki.2012.484 23364518.

6. Pai P, Bone J, McDicken I, Bell G. Solid tumour and glomerulopathy. QJM: An International Journal of Medicine. 1996;89(5):361–8.

7. Rihova Z, Honsova E, Merta M, Jancova E, Rysava R, Reiterova J, et al. Secondary Membranous Nephropathy—One Center Experience. Ren Fail. 2009;27(4):397–402. doi: 10.1081/jdi-65304 16060126

8. Pani A, Porta C, Cosmai L, Melis P, Floris M, Piras D, et al. Glomerular diseases and cancer: evaluation of underlying malignancy. J Nephrol. 2016;29(2):143–52. Epub 2015/10/27. doi: 10.1007/s40620-015-0234-9 26498294; PubMed Central PMCID: PMC4792341.

9. Sriskandarajah S, Bostad L, Myklebust TA, Moller B, Skrede S, Bjorneklett R. Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study. Int J Nephrol. 2017;2017:6013038. Epub 2018/02/07. doi: 10.1155/2017/6013038 29403663; PubMed Central PMCID: PMC5748316.

10. Alnasrallah B, Collins JF, Zwi LJ. Malignancy in Membranous Nephropathy: Evaluation of Incidence. Int J Nephrol. 2017;2017:8409829. Epub 2017/08/10. doi: 10.1155/2017/8409829 28791182; PubMed Central PMCID: PMC5534270.

11. Birkeland SA, Storm HH. Glomerulonephritis and malignancy: a population-based analysis. Kidney Int. 2003;63(2):716–21. Epub 2003/03/13. doi: 10.1046/j.1523-1755.2003.00771.x 12631139.

12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12. Epub 2009/05/06. doi: 10.7326/0003-4819-150-9-200905050-00006 19414839; PubMed Central PMCID: PMC2763564.

13. Davison A. Renal diseases associated with malignancies. Nephrology Dialysis Transplantation. 2001;16(suppl_6):13–4.

14. Eagen JW, Lewis EJ. Glomerulopathies of neoplasia. Elsevier; 1977.

15. Lien YH, Lai LW. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 2011;7(2):85–95. Epub 2010/12/15. doi: 10.1038/nrneph.2010.171 21151207; PubMed Central PMCID: PMC3058941.

16. Monga D, Jhaveri KD. Glomerular Diseases and Cancer. American Society of Nephrology Onco-Nephrology Curriculum. 2016:1–9.

17. Heaf JG, Hansen A, Laier GH. Quantification of cancer risk in glomerulonephritis. BMC Nephrol. 2018;19(1):27. Epub 2018/02/06. doi: 10.1186/s12882-018-0828-2 29394927; PubMed Central PMCID: PMC5797419.

18. Zlotnick A, Rosenmann E. Renal pathologic findings associated with monoclonal gammopathies. Arch Intern Med. 1975;135(1):40–5. 803364

19. Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8(9):1515–23. Epub 2013/05/25. doi: 10.2215/CJN.10491012 23704299; PubMed Central PMCID: PMC3805078.

20. Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012;59(6):786–94. Epub 2012/03/13. doi: 10.1053/j.ajkd.2011.12.028 22417785

21. von Vietinghoff S, Schneider W, Luft FC, Kettritz R. Crescentic glomerulonephritis and malignancy—guilty or guilt by association? Nephrol Dial Transplant. 2006;21(11):3324–6. Epub 2006/08/08. doi: 10.1093/ndt/gfl456 16891650.

22. Pankhurst T, Savage CO, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford). 2004;43(12):1532–5. Epub 2004/08/19. doi: 10.1093/rheumatology/keh374 15316126.

23. Baschinsky DY, Baker PB, Niemann TH, Wilmer WA. Pauci-immune ANCA-positive crescentic glomerulonephritis associated with metastatic adenocarcinoma of the lung. Am J Kidney Dis. 2000;36(4):e24. 1–e. 7. doi: 10.1053/ajkd.2000.17727 11007699

24. Edgar JD, Rooney DP, McNamee P, McNeill TA. An association between ANCA positive renal disease and malignancy. Clin Nephrol. 1993;40(1):22–5. Epub 1993/07/01. 8358871.

25. Hruby Z, Bronowicz A, Rabczyński J, Kopeć W, Szewczyk Z. A case of severe anti-neutrophil cytoplasmic antibody (ANCA)-positive crescentic glomerulonephritis and asymptomatic gastric cancer. Int Urol Nephrol. 1994;26(5):579–86. doi: 10.1007/bf02767663 7860209

26. Irish AB, Savdie E, Delprado W. Simultaneous presentation of gastric carcinoma and crescentic glomerulonephritis. Nephron. 1992;60(2):254. Epub 1992/01/01. doi: 10.1159/000186760 1553024.

27. Jhaveri KD, Shah HH, Patel C, Kadiyala A, Stokes MB, Radhakrishnan J. Glomerular diseases associated with cancer, chemotherapy, and hematopoietic stem cell transplantation. Adv Chronic Kidney Dis. 2014;21(1):48–55. Epub 2013/12/24. doi: 10.1053/j.ackd.2013.08.003 24359986.

28. Mustonen J, Pasternack A, Helin H. IgA Mesangial Nephropathy in Neoplastic Diseases1. IgA Mesangial Nephropathy. 40: Karger Publishers; 1984. p. 283–91. doi: 10.1159/000409763 6499458

29. Meyrier A, Delahousse M, Callard P, Rainfray M. Minimal change nephrotic syndrome revealing solid tumors. Nephron. 1992;61(2):220–3. Epub 1992/01/01. doi: 10.1159/000186877 1321349.

30. Mallouk A, Pham PT, Pham PC. Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol. 2006;10(4):284–9. Epub 2006/12/23. doi: 10.1007/s10157-006-0437-4 17186334.

31. Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006;70(8):1510–7. Epub 2006/08/31. doi: 10.1038/ 16941021.

32. Bjørneklett R, Vikse BE, Svarstad E, Aasarød K, Bostad L, Langmark F, et al. Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis. 2007;50(3):396–403. doi: 10.1053/j.ajkd.2007.06.003 17720518

33. Burstein DM, Korbet SM, Schwartz MM. Membranous Glomerulonephritis and Malignancy. Am J Kidney Dis. 1993;22(1):5–10. doi: 10.1016/s0272-6386(12)70160-9 8322793

34. Beck Jr LH, editor Membranous nephropathy and malignancy. Semin Nephrol; 2010: Elsevier. doi: 10.1016/j.semnephrol.2010.09.011 21146128

35. Biava CG, Gonwa TA, Naughton JL, Hopper J Jr. Crescentic glomerulonephritis associated with nonrenal malignancies. Am J Nephrol. 1984;4(4):208–14. doi: 10.1159/000166810 6548083

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden